Clinical Trial
1) The beginning
2) Relation: MD - patient
3) How it works
4) A surprising Imaging
5) Risk Assessment
Our Solution
Our one-of-a-kind solution is the PatScope imager to reveal Lesion Distortions at an EARLY stage. These distortions are the precursor of skin cancer and cosmetic abnormalities. We are the first in history with this sort of imaging.
> The higher the distortion, the higher the risk of skin cancer.
> PatScope Imaging includes information about the surrounding distortions of a lesion. Something that was neglected in the past and now helps to understand the risk and the prioritization to remove the right lesion first.
Clinical Trial Protocol
The scans were performed on lesions found by a board-certified dermatologist that was about to be biopsied. The patient consented and the scan was performed.
We expect that lesions with atypia will have prominent lateral movement of the backscattered light (LMB) with no random patterns.
In non-atypical lesions, we expect a random LMB. To confirm our suspicions the scans were correlated with histology.
To be able to monitor in-between distortion situations we scanned two tissue conditions
-
Atypic: MM, SCC,BCC
-
Not Atypic: SK, ISK, DN
Biopsy consent
We may possibly scan the lesions with the Patternox scope (PatScope); these scans will be used for research and possibly publication. The PatScope is a non-invasive visible light to examine the backscattered light produced from the scan of the skin. There will be no identifiable data released to a third party.